BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 28939130)

  • 61. Immunotherapy response modeling by ex-vivo organ culture for lung cancer.
    Kamer I; Bab-Dinitz E; Zadok O; Ofek E; Gottfried T; Daniel-Meshulam I; Hout-Siloni G; Ben Nun A; Barshack I; Onn A; Bar J
    Cancer Immunol Immunother; 2021 Aug; 70(8):2223-2234. PubMed ID: 33484295
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Immunoregulatory molecules in patients with gestational diabetes mellitus.
    Pendeloski KP; Mattar R; Torloni MR; Gomes CP; Alexandre SM; Daher S
    Endocrine; 2015 Sep; 50(1):99-109. PubMed ID: 25754913
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Elevated frequencies of CD8 T cells expressing PD-1, CTLA-4 and Tim-3 within tumour from perineural squamous cell carcinoma patients.
    Linedale R; Schmidt C; King BT; Ganko AG; Simpson F; Panizza BJ; Leggatt GR
    PLoS One; 2017; 12(4):e0175755. PubMed ID: 28423034
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Emerging immunotherapies in the treatment of non-small cell lung cancer (NSCLC): the role of immune checkpoint inhibitors.
    Langer CJ
    Am J Clin Oncol; 2015 Aug; 38(4):422-30. PubMed ID: 24685885
    [TBL] [Abstract][Full Text] [Related]  

  • 65. NFATc1 Promotes Antitumoral Effector Functions and Memory CD8
    Heim L; Friedrich J; Engelhardt M; Trufa DI; Geppert CI; Rieker RJ; Sirbu H; Finotto S
    Cancer Res; 2018 Jul; 78(13):3619-3633. PubMed ID: 29691251
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Expression of PD1 and BTLA on the CD8
    Bao Y; Mo JF; Wu JY; Cao CX
    Chin Med Sci J; 2019 Nov; 34(4):248-255. PubMed ID: 33906710
    [No Abstract]   [Full Text] [Related]  

  • 67. Function and regulation of LAG3 on CD4
    Ma QY; Huang DY; Zhang HJ; Wang S; Chen XF
    Exp Cell Res; 2017 Nov; 360(2):358-364. PubMed ID: 28935468
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Analyzing the percentage of different PD-1
    Hu X; Gu Y; Li D; Zhao S; Hua S; Jiang Y
    Clin Exp Pharmacol Physiol; 2019 Dec; 46(12):1074-1083. PubMed ID: 31381177
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Interleukin-35 Suppresses the Antitumor Activity of T Cells in Patients with Non-Small Cell Lung Cancer.
    Wang HM; Zhang XH; Feng MM; Qiao YJ; Ye LQ; Chen J; Fan FF; Guo LL
    Cell Physiol Biochem; 2018; 47(6):2407-2419. PubMed ID: 29991058
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma.
    Yang CY; Lin MW; Chang YL; Wu CT; Yang PC
    Eur J Cancer; 2016 Apr; 57():91-103. PubMed ID: 26901614
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Circulating activated immune cells as a potential blood biomarkers of non-small cell lung cancer occurrence and progression.
    Wang Y; Zhou N; Zhu R; Li X; Sun Z; Gao Y; Liu W; Meng C; Ge Y; Bai C; Li T; Liu H
    BMC Pulm Med; 2021 Sep; 21(1):282. PubMed ID: 34488711
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Local CD4+, CD8+ and CD56+ reactions to lung cancer in regard to pathohistological type and clinical stage.
    Jusufovic E; Iljazovic E; Kosnik M; Keser D; Korosec P; Zukic E; Prnjavorac B; Sejdinović R; Ajanović E
    Med Glas (Zenica); 2011 Feb; 8(1):101-8. PubMed ID: 21263406
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Impact of the immune cell population in peripheral blood on response and survival in patients receiving neoadjuvant chemotherapy for advanced gastric cancer.
    He Q; Li G; Ji X; Ma L; Wang X; Li Y; Fan C
    Tumour Biol; 2017 May; 39(5):1010428317697571. PubMed ID: 28475005
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Prognostic value of the immunological phenomena and relationship with clinicopathological characteristics of the tumor--the expression of the early CD69+, CD71+ and the late CD25+, CD26+, HLA/DR+ activation markers on T CD4+ and CD8+ lymphocytes in squamous cell laryngeal carcinoma. Part II.
    Starska K; Głowacka E; Kulig A; Lewy-Trenda I; Bryś M; Lewkowicz P
    Folia Histochem Cytobiol; 2011; 49(4):593-603. PubMed ID: 22252753
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The Role of Circulating T Follicular Helper Cells and Regulatory Cells in Non-Small Cell Lung Cancer Patients.
    Guo Z; Liang H; Xu Y; Liu L; Ren X; Zhang S; Wei S; Xu P
    Scand J Immunol; 2017 Aug; 86(2):107-112. PubMed ID: 28513867
    [TBL] [Abstract][Full Text] [Related]  

  • 76. HIV-1-infected children on HAART: immunologic features of three different levels of viral suppression.
    Zaccarelli-Filho CA; Ono E; Machado DM; Brunialti M; Succi RC; Salomão R; Kallás EG; de Moraes-Pinto MI
    Cytometry B Clin Cytom; 2007 Jan; 72(1):14-21. PubMed ID: 17041945
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Changes in systemic immune response after stereotactic ablative radiotherapy. Preliminary results of a prospective study in patients with early lung cancer.
    Rutkowski J; Ślebioda T; Kmieć Z; Zaucha R
    Pol Arch Intern Med; 2017 Apr; 127(4):245-253. PubMed ID: 28420863
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade.
    McGranahan N; Furness AJ; Rosenthal R; Ramskov S; Lyngaa R; Saini SK; Jamal-Hanjani M; Wilson GA; Birkbak NJ; Hiley CT; Watkins TB; Shafi S; Murugaesu N; Mitter R; Akarca AU; Linares J; Marafioti T; Henry JY; Van Allen EM; Miao D; Schilling B; Schadendorf D; Garraway LA; Makarov V; Rizvi NA; Snyder A; Hellmann MD; Merghoub T; Wolchok JD; Shukla SA; Wu CJ; Peggs KS; Chan TA; Hadrup SR; Quezada SA; Swanton C
    Science; 2016 Mar; 351(6280):1463-9. PubMed ID: 26940869
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Circulating CD137
    Nong J; Wang J; Gao X; Zhang Q; Yang B; Yan Z; Wang X; Yi L; Wang Q; Gao Y; Hu A; Qin N; Wei P; Zhang H; Zhang S
    Scand J Immunol; 2019 Jun; 89(6):e12765. PubMed ID: 30921475
    [TBL] [Abstract][Full Text] [Related]  

  • 80. T cell profiling reveals high CD4+CTLA-4 + T cell frequency as dominant predictor for survival after prostate GVAX/ipilimumab treatment.
    Santegoets SJ; Stam AG; Lougheed SM; Gall H; Scholten PE; Reijm M; Jooss K; Sacks N; Hege K; Lowy I; Cuillerot JM; von Blomberg BM; Scheper RJ; van den Eertwegh AJ; Gerritsen WR; de Gruijl TD
    Cancer Immunol Immunother; 2013 Feb; 62(2):245-56. PubMed ID: 22878899
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.